Search Results 721-730 of 17180 for senescent cells senolytic
The purpose of this study is to provide access to CTL019 through Managed Access Program (MAP) for acute lymphoblastic leukemia (ALL) or diffuse large b-cell ...
... cells. Romidepsin and lenalidomide may stop the growth of cancer cells by blocking enzymes needed for cell growth. Giving rituximab together with romidepsin ...
... cells or T-cell engager therapy such as bispecific and trispecific antibodies and the factors that may determine disease progression and treatment response.
Matveyenko's team also is discovering how circadian clock genes and the circadian system regulate beta cell function and regeneration. Circadian disruption in ...
The Islet Regeneration Lab of Aleksey Matveyenko, Ph.D., at Mayo Clinic studies restoring and regenerating pancreatic beta cell function in diabetes.
The primary objectives for this study are: The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 6 months of ...
Learn about the symptoms, causes and treatment of this inherited blood disorder that, in the United States, is more common among Black people.
These therapeutic antibodies and their derivatives have transformed the therapeutic landscape of cancer patients. Only 20% of cell-surface proteins have been ...
Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with ...
Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!